^
    24h
    Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib. (PubMed, NPJ Precis Oncol)
    Among the three paradigms, MET-specific monitoring provided the most favorable diagnostic performance to identify long-term responders, with a specificity of 90% and a positive predictive value of 80%. These data demonstrate that early MET-specific ctDNA clearance is a robust on-treatment biomarker for ensartinib benefit in METex14 NSCLC, while broader ctDNA profiling remains valuable for uncovering emerging resistance mechanisms.
    Journal • Circulating tumor DNA
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    Ensacove (ensartinib)
    24h
    Treating Patients With Melanoma and ALK Alterations With Ensartinib (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    BRAF V600 • ALK fusion • ALK mutation
    |
    Ensacove (ensartinib)
    1d
    A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out. (clinicaltrials.gov)
    P=N/A, N=35, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=500 --> 35 | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Real-world evidence
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 positive
    |
    Lorbrena (lorlatinib)
    2d
    CUBIK: Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Fundación GECP | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial primary completion date • Liquid biopsy
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK rearrangement
    |
    VENTANA ALK (D5F3) CDx Assay
    |
    Alunbrig (brigatinib)
    2d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=71, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)
    2d
    Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial. (PubMed, Nat Med)
    These results support the use of repotrectinib to treat patients with NTRK+ solid tumors. ClinicalTrials.gov identifier: NCT03093116 .
    P1/2 data • Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    Augtyro (repotrectinib)
    2d
    Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement. (PubMed, Cancer Med)
    The progression modes of ROS1 rearrangement may predict survival benefits and provide subsequent treatment strategies in ROS1-rearranged NSCLC.
    Retrospective data • Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 rearrangement
    |
    Xalkori (crizotinib)
    2d
    Pediatric inflammatory myofibroblastic tumor of the urinary bladder: a rare case report and treatment approach. (PubMed, Turk J Pediatr)
    Partial cystectomy was performed, but due to positive surgical margins and recurrent hematuria, targeted therapy with crizotinib was initiated based on anaplastic lymphoma kinase (ALK) positivity...This case highlights the importance of a multidisciplinary approach involving surgery, pathology, and oncology. Further pediatric-focused studies are warranted to refine treatment strategies and define long-term outcomes.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    Xalkori (crizotinib)
    3d
    Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    ALK rearrangement
    |
    Opdivo (nivolumab) • Zykadia (ceritinib)
    4d
    A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors. (PubMed, Genome Biol)
    This study provides a comprehensive functional atlas of ALK tyrosine kinase domain variants under TKI selection, offering a valuable experimental framework for interpreting resistance-associated variants. Although derived from in vitro models and therefore context dependent, this resource complements existing clinical and genomic knowledge and may aid in the functional interpretation of ALK variants observed in ALK-driven cancers.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion • ALK G1202R
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib)
    5d
    SAILOR: Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Peking University Shenzhen Hospital
    New trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib) • Qi Xinke (iruplinalkib)